Real-life experience with benralizumab during 6 months
Abstract Background Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, suf...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-06-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12890-020-01220-9 |
| _version_ | 1819043640217960448 |
|---|---|
| author | A. Padilla-Galo RCh Levy-Abitbol C. Olveira B. Valencia Azcona M. Pérez Morales F. Rivas-Ruiz B. Tortajada-Goitia I. Moya-Carmona A. Levy-Naon |
| author_facet | A. Padilla-Galo RCh Levy-Abitbol C. Olveira B. Valencia Azcona M. Pérez Morales F. Rivas-Ruiz B. Tortajada-Goitia I. Moya-Carmona A. Levy-Naon |
| author_sort | A. Padilla-Galo |
| collection | DOAJ |
| description | Abstract Background Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-life evidence is lacking to confirm the efficacy and safety data from clinical trials. The purpose of this study was to evaluate the efficacy and safety of benralizumab for the treatment of severe refractory eosinophilic asthma in a real-world cohort of patients. Methods This was a cross-sectional multicentre study of consecutive patients with severe refractory eosinophilic asthma who received treatment with benralizumab during at least 6 months. Patient follow-up was performed in specialised severe asthma units. Results A total of 42 patients were enrolled and treated with benralizumab. Asthma control, as measured by the asthma control test (ACT), improved in all patients both at 3 months of treatment compared with baseline (13.9 ± 4 vs 20.1 ± 3.7, p < 0.001) and at 6 months of treatment compared with the results obtained at 3 months (20.1 ± 3.7 vs 21 ± 2.7, p = 0.037). Similarly, the number of emergency department visits decreased both at 3 months compared with baseline (1 [IR:0.7] vs 0 [IR:0.75], p < 0.001) and at 6 months compared with the results at 3 months (0 [IR:0.75] vs 0 [IR:0], p = 0.012). Reductions in the number of oral corticosteroid cycles, percentage of corticosteroid-dependent patients, and mean daily dose of oral or inhaled corticosteroid were also evidenced. Finally, mean lung function improvement was 291 mL (p < 0.001), and FEV1% improved both at 3 months compared with baseline (64.4 ± 9.3 vs 73.1 ± 9.1, p < 0.001) and at 6 months compared to 3 months (73.1 ± 9.1 vs 76.1 ± 12, p = 0.002). Side effects were mild and did not lead to treatment discontinuation. Conclusions This study confirms the efficacy and safety of benralizumab in a real-life setting with improved asthma control and lung function, and a reduced oral and inhaled corticosteroid use as well as fewer emergency department visits. In addition to a rapid initial improvement, it appears that patients continue to improve during the first 6 months of treatment. |
| first_indexed | 2024-12-21T10:00:00Z |
| format | Article |
| id | doaj.art-927ef4563ea249bf88ce7e5e4ab07d4e |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-12-21T10:00:00Z |
| publishDate | 2020-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-927ef4563ea249bf88ce7e5e4ab07d4e2022-12-21T19:07:57ZengBMCBMC Pulmonary Medicine1471-24662020-06-0120111210.1186/s12890-020-01220-9Real-life experience with benralizumab during 6 monthsA. Padilla-Galo0RCh Levy-Abitbol1C. Olveira2B. Valencia Azcona3M. Pérez Morales4F. Rivas-Ruiz5B. Tortajada-Goitia6I. Moya-Carmona7A. Levy-Naon8Pneumology UnitYeshiva UniversityPneumology Department, IBIMA (Institute for Biomedical Research of Málaga), Regional University Hospital of Málaga/ University of MálagaPneumology UnitPneumology UnitResearch Unit, Red de Investigación en Servicios de Salud en Enfermedades Crónicas, REDISSEC (Spanish healthcare network for chronic diseases)Pharmacy and Nutrition ServicePharmacy and Nutrition Service, Hospital Universitario Virgen de la VictoriaPneumology Department, Hospital Universitario Virgen de la VictoriaAbstract Background Benralizumab is a monoclonal antibody that binds to the human interleukin-5 (IL-5) receptor (IL-5R), thereby preventing IL-5 from binding to its receptor and inhibiting differentiation and maturation of eosinophils in the bone marrow. Because of its recent marketing approval, sufficient real-life evidence is lacking to confirm the efficacy and safety data from clinical trials. The purpose of this study was to evaluate the efficacy and safety of benralizumab for the treatment of severe refractory eosinophilic asthma in a real-world cohort of patients. Methods This was a cross-sectional multicentre study of consecutive patients with severe refractory eosinophilic asthma who received treatment with benralizumab during at least 6 months. Patient follow-up was performed in specialised severe asthma units. Results A total of 42 patients were enrolled and treated with benralizumab. Asthma control, as measured by the asthma control test (ACT), improved in all patients both at 3 months of treatment compared with baseline (13.9 ± 4 vs 20.1 ± 3.7, p < 0.001) and at 6 months of treatment compared with the results obtained at 3 months (20.1 ± 3.7 vs 21 ± 2.7, p = 0.037). Similarly, the number of emergency department visits decreased both at 3 months compared with baseline (1 [IR:0.7] vs 0 [IR:0.75], p < 0.001) and at 6 months compared with the results at 3 months (0 [IR:0.75] vs 0 [IR:0], p = 0.012). Reductions in the number of oral corticosteroid cycles, percentage of corticosteroid-dependent patients, and mean daily dose of oral or inhaled corticosteroid were also evidenced. Finally, mean lung function improvement was 291 mL (p < 0.001), and FEV1% improved both at 3 months compared with baseline (64.4 ± 9.3 vs 73.1 ± 9.1, p < 0.001) and at 6 months compared to 3 months (73.1 ± 9.1 vs 76.1 ± 12, p = 0.002). Side effects were mild and did not lead to treatment discontinuation. Conclusions This study confirms the efficacy and safety of benralizumab in a real-life setting with improved asthma control and lung function, and a reduced oral and inhaled corticosteroid use as well as fewer emergency department visits. In addition to a rapid initial improvement, it appears that patients continue to improve during the first 6 months of treatment.http://link.springer.com/article/10.1186/s12890-020-01220-9AsthmaBenralizumabEosinophilsBiologicsSevere asthmaEosinophilic asthma |
| spellingShingle | A. Padilla-Galo RCh Levy-Abitbol C. Olveira B. Valencia Azcona M. Pérez Morales F. Rivas-Ruiz B. Tortajada-Goitia I. Moya-Carmona A. Levy-Naon Real-life experience with benralizumab during 6 months BMC Pulmonary Medicine Asthma Benralizumab Eosinophils Biologics Severe asthma Eosinophilic asthma |
| title | Real-life experience with benralizumab during 6 months |
| title_full | Real-life experience with benralizumab during 6 months |
| title_fullStr | Real-life experience with benralizumab during 6 months |
| title_full_unstemmed | Real-life experience with benralizumab during 6 months |
| title_short | Real-life experience with benralizumab during 6 months |
| title_sort | real life experience with benralizumab during 6 months |
| topic | Asthma Benralizumab Eosinophils Biologics Severe asthma Eosinophilic asthma |
| url | http://link.springer.com/article/10.1186/s12890-020-01220-9 |
| work_keys_str_mv | AT apadillagalo reallifeexperiencewithbenralizumabduring6months AT rchlevyabitbol reallifeexperiencewithbenralizumabduring6months AT colveira reallifeexperiencewithbenralizumabduring6months AT bvalenciaazcona reallifeexperiencewithbenralizumabduring6months AT mperezmorales reallifeexperiencewithbenralizumabduring6months AT frivasruiz reallifeexperiencewithbenralizumabduring6months AT btortajadagoitia reallifeexperiencewithbenralizumabduring6months AT imoyacarmona reallifeexperiencewithbenralizumabduring6months AT alevynaon reallifeexperiencewithbenralizumabduring6months |